Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,235 total articles
ArriVent BioPharma (AVBP) is a clinical-stage oncology name trading at roughly $22.34 with a market cap near $981M. Recent company activity - including AACR preclinical posters and a pivot into a global Phase 3 for firmonertinib - has created a binary investment case. If a short scheduling delay is used to refine endpoints, broaden inclusion criter…
Planet Labs (PL) has gone from a beaten-down name to one of 2025-26's high flyers. With Q4 revenue surprise, bullish guidance and AI/defense catalysts, the stock looks bid — but valuation and momentum leave little margin for error. This note lays out a concrete trade: harvest partial profits now, protect a core position with a trailing stop, and a …
MDA has reported record top-line traction and is visibly pivoting more of its business mix toward defense programs. That combination supports upside through contract awards and backlog conversion over the next 3-9 months. This trade idea is a tactical long looking to capture program wins and margin improvement while keeping a tight stop to limit pr…
H World Group delivered a solid Q4 revenue beat and is rolling out Hanting Inn, a low-capex economy brand that could accelerate unit growth and margins. Against a $15.8B market cap, a modest P/E of 22.5 and a 3.5% dividend yield, the risk/reward favors a long trade toward $58 if management can sustain revenue/margin improvement into 2026. Entry $49…
Huntington (HBAN) trades near $15.45, a valuation that looks inexpensive relative to growth and free cash flow, while near-term catalysts (merger synergies, sector momentum, and dividend yield) could re-rate the stock. The trade below is a mid-term swing (45 trading days) long with a clear stop and target. This is not a blind buy — credit trends an…
10x Genomics (TXG) is an actionable long: the stock trades at a $2.45B market cap, is generating meaningful free cash flow ($130.1M trailing), and is moving toward a higher-margin, consumables-led revenue mix that should compress multiples and re-rate the shares. Technicals are neutral and short interest remains material, so use a defined entry and…
Alpha Tau Medical (DRTS) is a clinical-stage oncology company focused on Alpha DaRT diffusing alpha-emitter radiation therapy. The stock is trading near $7.20 with a market cap of about $634M. 2026 carries multiple catalysts and an expanding radiopharmaceutical market backdrop. This trade idea lays out an actionable long position with precise entry…
This trade idea targets a diversified royalty vehicle whose model emphasizes fixed-dollar royalties instead of percentage-of-revenue or commodity-linked streams. The idea: buy into a de-risked payout profile at an entry of $10.00, use a tight stop at $8.00, and take profits at $14.00 over a mid-term (45 trading days) horizon. Rationale: steady cash…
Preformed Line Products (PLPC) is a high-quality, niche infrastructure supplier benefiting from secular grid and broadband upgrades. Strong recent revenue growth, clean balance sheet, and improving margins justify a long-biased trade. Entry $275.00, target $330.00, stop $245.00 for a long-term (180 trading days) hold.
Astronics (ATRO) is trading at $66.03 after a pullback from its 52-week high. The company benefits from accelerating aircraft lighting demand, a strategic acquisition that should add ~$22M in run-rate revenue, and improving free cash flow. Valuation is rich on a P/E basis but reasonable on an EV/sales lens given aerospace peers and growth expectati…
Propel Holdings appears to trade at a valuation that understates its growth runway and optionality in payments and enterprise software. This trade idea lays out a clear entry, stop, and target with a mid-term hold to let catalysts and margin expansion play out.
MDA Space ($32.56) trades like a high-growth story but now carries stretched multiples (P/E 50.2, P/B 4.0) and declining technicals. With price well below short-term moving averages, heavy short interest on recent volume spikes, and upcoming execution-dependent milestones across Robotics and Satellite Systems, the easy upside is largely priced in. …
Greg Abel's early actions as CEO - a personal $15M buy and the restart of repurchases - create an actionable long trade on Berkshire Hathaway. Valuation looks reasonable (P/E ~15, P/B ~1.44) while FCF and a $1.04T market cap anchor upside. This trade targets a rebound toward the upper half of the 52-week range over a 180-trading-day horizon, with a…
Micron is trading well below its recent highs after a market pullback, but underlying fundamentals - low leverage, double-digit free cash flow, and sold-out HBM capacity - look very similar to the early stages of Nvidia's profit re-rating. This is a tradeable long: enter at $405.00, stop at $360.00, target $550.00 over a long-term, 180 trading day …
Trinity Capital (TRIN) offers a compelling income entry today: a monthly $0.17 dividend (14%+ yield) backed by a growing investment book, modest valuation (P/B ~1.07, P/E ~7.3) and a market cap around $1.2B. The trade targets mean reversion toward recent highs while collecting outsized cash distribution; downside is controlled with a sub-$13 stop i…
Apogee Therapeutics (APGE) is a clinical-stage biotech that just put itself squarely in the market's spotlight: compelling 16-week Phase 2 data, a long half-life TSLP program enabling infrequent dosing, and a 52-week APEX readout on 03/23/2026. This trade idea lays out a defined long with entry, stop and target for a long-term swing (180 trading da…
Novartis ($148.09) is executing against a diversified growth playbook: bolt-on M&A (SNV4818), dermatology approvals, and external licensing add near-term revenue and long-term optionality. Valuation is reasonable for a large-cap pharma with $8.17B FCF and a $313.9B market cap. Trade long with a $170 target and $135 stop while monitoring clinical re…
Lyell's dual-targeting CAR-T (ronde-cel / LYL314) has delivered impressive early response data and the company just closed a $50M tranche that extends runway into Q2 2027. The story remains fundamentally attractive, but the path to commercialization and financing risk keep this a high-volatility trade. We outline a tactical long with strict stops a…
SoFi (SOFI) has been punished recently by a secondary offering, a high-profile short report and crypto-related headline risk. The business, however, still posted $3.61B in 2025 revenue (+35% YoY), 13.7M members (+35%) and reported GAAP profitability across recent quarters. With a market cap near $21.9B, conservative leverage and insider buying, the…
Cloudflare is expensive on headline multiples, but its role as global edge infrastructure and recent momentum make a tactical add attractive. I personally loaded at $170 and plan to add if shares pull back to $210, with a stop at $195 and a primary target near the 52-week high at $260. The trade is driven by accelerating enterprise deal flow, impro…
Nvidia remains the engine of the AI data-center cycle: $4.33T market cap, exceptional ROE and free cash flow, and low leverage. Near-term selling has pushed momentum indicators into neutral-to-bearish territory, but fundamentals and catalysts (AI demand, new energy partnerships, industry spend signals) argue for a mid-term rebound. I outline a clea…
Brookfield Infrastructure offers a near-5% distribution yield, diversified regulated and contracted cash flows, and optional upside from growing AI-related data center demand. The balance between reliable yields and price optionality — with a market cap of roughly $16.5B and a 52-week range of $25.72-$40.32 — creates a pragmatic long trade for inco…
Rivian just landed a material commercial and capital partnership with Uber and is rolling into the mass-market R2 launch. The deal reduces funding uncertainty and creates a large potential buyer for up to 50,000 autonomous vehicles; combine that with improving technical momentum and you have a tradable long setup with defined risk-reward.
Salesforce is trading near $195 while the market digests headlines about AI displacing software subscriptions. That narrative misses the point: Salesforce is structurally advantaged as enterprises move to agentic AI because it owns customer data, identity plumbing and an expanding AI revenue stream. With $14.4B in free cash flow, a market cap of ~$…
Marvell sits at the junction of two durable trends: the shift to custom AI processors and the compounding need for higher-bandwidth data-center interconnects. Trading at roughly $90 with a market cap near $79B, the stock offers a leveraged way to play AI infrastructure without buying a pure GPU vendor. This trade idea lays out entry, stop, targets …
